Non-muscle-invasive bladder cancer: a vision for the future

References

• Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011;12:933–80.
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012; 2012. Available from: http://globocan.iarc.fr.
   Google Scholar
• Babjuk M, Böhle A, Burger M, Compérat E, Kaasinen E, Palou J, et al. Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS). Arnhem, The Netherlands: European Association of Urology; 2016.
   Google Scholar
• Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer. AUA/SUO guideline; 2016. Available from: http://www.auanet.org/education/guidelines/non-muscle-invasive-bladder-cancer.cfm.
   Google Scholar
• Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic burden of bladder cancer across the European Union. Eur Urol 2016;69:438–47.
   PubMed Web of Science ®Google Scholar
• Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005;5:713–25.
   PubMed Web of Science ®Google Scholar
• Chou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, et al. Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis. Ann Intern Med 2015;163:922–31.
   PubMed Web of Science ®Google Scholar
• Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 2015;15:25–41.
   PubMed Web of Science ®Google Scholar
• Scher MB, Elbaum MB, Mogilevkin Y, Hilbert DW, Mydlo JH, Sidi AA, et al. Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. J Urol 2012;188:2101–7.
   PubMed Web of Science ®Google Scholar
• Rosser CJ, Liu L, Sun Y, Villicana P, McCullers M, Porvasnik S, et al. Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev 2009;18:444–53.
   PubMed Web of Science ®Google Scholar
• Goodison S, Chang M, Dai Y, Urquidi V, Rosser CJ. A multi-analyte assay for the non-invasive detection of bladder cancer. PLoS One 2012;7:e47469.
   PubMed Web of Science ®Google Scholar
• Horstmann M, Steinbach D, Fischer C, Enkelmann A, Grimm M-O, Voss A. An electronic nose system detects bladder cancer in urine specimen: first results of a pilot study. New Orleans (LA): American Urological Association Annual Meeting; 2015.
   Google Scholar
• Helenius M, Brekkan E, Dahlman P, Lönnemark M, Magnusson A. Bladder cancer detection in patients with gross haematuria: computed tomography urography with enhancement-triggered scan versus flexible cystoscopy. Scand J Urol 2015;49:377–81.
   PubMed Web of Science ®Google Scholar
• Zhai N, Wang YH, Zhu LM, Wang JH, Sun XH, Hu XB, et al. Sensitivity and specificity of diffusion-weighted magnetic resonance imaging in diagnosis of bladder cancers. Clin Invest Med 2015;38:E173–84.
   PubMed Web of Science ®Google Scholar
• Zlatev DV, Altobelli E, Liao JC. Advances in imaging technologies in the evaluation of high-grade bladder cancer. Urol Clin North Am 2015;42:147–57.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Bladder cancer: diagnosis and management. NICE guidelines NG2; 2015. Available from: http://www.nice.org.uk/guidance/ng2 [last accessed February 2015].
   Google Scholar
• Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 2013;64:846–54.
   PubMed Web of Science ®Google Scholar
• Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int 2011;108:E297–303.
   PubMed Web of Science ®Google Scholar
• Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010;184:1907–13.
   PubMed Web of Science ®Google Scholar
• Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012;188:58–62.
   PubMed Web of Science ®Google Scholar
• Lamm D, Persad R, Brausi M, Buckley R, Witjes JA, Palou J, et al. Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. J Urol 2014;191:20–7.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Cookson M, Witjes JA, Stenzl A, Grossman HB. The impact of blue light cystoscopy with hexaminolevulinate (HAL) on progression of bladder cancer: a new analysis. Bladder Cancer 2016;2:273–8.
   PubMedGoogle Scholar
• Mariappan P, Rai B, El-Mokadem I, Anderson CH, Lee H, Stewart S, Donat R. Real-life experience: early recurrence with Hexvix photodynamic diagnosis–assisted transurethral resection of bladder tumour (TURBT) vs good-quality white light TURBT in new non-muscle-invasive bladder cancer. Urology 2015;86:327–31.
   PubMed Web of Science ®Google Scholar
• Lykke MR, Nielsen TK, Ebbensgaard NA, Zieger K. Reducing recurrence in non-muscle-invasive bladder cancer using photodynamic diagnosis and immediate post-transurethral resection of the bladder chemoprophylaxis. Scand J Urol 2015;49:230–6.
   PubMed Web of Science ®Google Scholar
• O’Brien T, Ray E, Chatterton K, Khan MS, Chandra A, Thomas K. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer. BJU Int 2013;112:1096–104.
   PubMed Web of Science ®Google Scholar
• Rose JB, Armstrong S, Hermann GG, Kjellberg J, Malmström PU. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cystoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden. BJU Int 2016;117:E102–13.
   PubMed Web of Science ®Google Scholar
• Zheng C, Lv Y, Zhong Q, Wang R, Jiang Q. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int 2012;110:E680–7.
   PubMed Web of Science ®Google Scholar
• Naselli A, Introini C, Timossi L, Spina B, Fontana V, Pezzi R, et al. A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. Eur Urol 2012;61:908–13.
   PubMed Web of Science ®Google Scholar
• Geavlete B, Multesco R, Georgescu D, Stanescu F, Jecu M, Geavlete P. Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors – results of a prospective, randomized comparison to the standard approach. Urology 2012;79:846–51.
   PubMed Web of Science ®Google Scholar
• Naito S, Algaba F, Babjuk M, Bryan RT, Sun YH, Valiquette L, de la Rosette J. The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur Urol 2016;70:506–15.
   PubMed Web of Science ®Google Scholar
• Lee JY, Cho KS, Kang DH, Jung HD, Kwon JK, Oh CK, et al. A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging. BMC Cancer 2015;15:566.
   PubMed Web of Science ®Google Scholar
• Kamphuis GM, de Bruin DM, Brandt MJ, Knoll T, Conort P, Lapini A, et al. Comparing image perception of bladder tumors in four different Storz professional image enhancement system modalities using the íSPIES app. J Endourol 2016;30:602–8.
   PubMed Web of Science ®Google Scholar
• Geavlete P, Stanescu F, Ene C, Bulai C, Moldoveanu C, Jecu M, et al. SPIES versus NBI technology in bladder tumors’ diagnostic [abstract MP38-21]. London (UK): World Congress of Endourology; 2015.
   Google Scholar
• Gravas S, Stenzl A. The Storz professional image enhancement system (SPIES) nonmuscle-invasive bladder cancer study: a multicenter international randomized controlled study. J Endourol 2014;28:1254–5.
   PubMed Web of Science ®Google Scholar
• Hermes B, Spöler F, Naami A, Bornemann J, Först M, Grosse J, et al. Visualization of the basement membrane zone of the bladder by optical coherence tomography: feasibility of noninvasive evaluation of tumor invasion. Urology 2008;72:677–81.
   PubMed Web of Science ®Google Scholar
• Ren H, Waltzer WC, Bhalla R, Liu J, Yuan Z, Lee CSD, et al. Diagnosis of bladder cancer with microelectromechanical systems-based cystoscopic optical coherence tomography. Urology 2009;74:1351–7.
   PubMed Web of Science ®Google Scholar
• Karl A, Stepp H, Willmann E, Buchner A, Hocaoglu Y, Stief C, Tritschler S. Optical coherence tomography for bladder cancer – ready as a surrogate for optical biopsy? Results of a prospective mono-centre study. Eur J Med Res 2010;15:131–4.
   PubMed Web of Science ®Google Scholar
• Schmidbauer J, Remzi M, Klatte T, Waldert M, Mauermann J, Susani M, Marberger M. Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol 2009;56:914–19.
   PubMed Web of Science ®Google Scholar
• Vendrell M, Maiti KK, Dhaliwal K, Chang YT. Surface-enhanced Raman scattering in cancer detection and imaging. Trends Biotechnol 2013;31:249–57.
   PubMed Web of Science ®Google Scholar
• Dochow S, Bergner N, Matthäus C, Praveen BB, Ashok PC, Mazilu M, et al. Etaloning, fluorescence and ambient light suppression by modulated wavelength Raman spectroscopy. Biomed Spectrosc Imaging 2012;1:383–9.
   Google Scholar
• Draga RO, Grimbergen MC, Vijverberg PL, van Swol CF, Jonges TG, Kummer JA, Ruud Bosch JL. In vivo bladder cancer diagnosis by high-volume Raman spectroscopy. Anal Chem 2010;82:5993–9.
   PubMed Web of Science ®Google Scholar
• Sonn GA, Jones SN, Tarin TV, Du CB, Mach KE, Jensen KC, Liao JC. Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J Urol 2009;182:1299–305.
   PubMed Web of Science ®Google Scholar
• Wu K, Liu JJ, Adams W, Sonn GA, Mach KE, Pan Y, et al. Dynamic real-time microscopy of the urinary tract using confocal laser endomicroscopy. Urology 2011;78:225–31.
   PubMed Web of Science ®Google Scholar
• Jain M, Robinson BD, Scherr DS, Sterling J, Lee MM, Wysock J, et al. Multiphoton microscopy in the evaluation of human bladder biopsies. Arch Pathol Lab Med 2012;136:517–26.
   PubMed Web of Science ®Google Scholar
• Jain M, Robinson BD, Shevchuk MM, Aggarwal A, Salamoon B, Dubin JM, et al. Multiphoton microscopy: a potential intraoperative tool for the detection of carcinoma in situ in human bladder. Arch Pathol Lab Med 2015;139:796–804.
   PubMed Web of Science ®Google Scholar
• Zhao C, Tang K, Yang H, Xia D, Chen Z. Bipolar versus monopolar transurethral resection of nonmuscle-invasive bladder cancer: a meta-analysis. J Endourol 2016;30:5–12.
   PubMed Web of Science ®Google Scholar
• Engilbertsson H, Aaltonen KE, Björnsson S, Kristmundsson T, Patschan O, Rydén L, Gudjonsson S. Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream. J Urol 2015;193:53–7.
   PubMed Web of Science ®Google Scholar
• Hermann GG, Mogensen K, Lindvold LR, Haak CS, Haedersdal M. Office-based transurethral devascularisation of low grade non-invasive urothelial cancer using diode laser. A feasibility study. Lasers Surg Med 2015;47:620–5.
   PubMed Web of Science ®Google Scholar
• Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, et al. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/grade 3 bladder cancer treated with bacille Calmette-Guérin. BJU Int 2016;118:44–52.
   PubMed Web of Science ®Google Scholar
• Otto W, Denzinger S, Fritsche HM, Burger M, Wieland WF, Hofstädter F, et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int 2011;107:404–8.
   PubMed Web of Science ®Google Scholar
• Lokeshwar SD, Ruiz-Cordero R, Hupe MC, Jorda M, Soloway MS. Impact of 2004 ISUP/WHO classification on bladder cancer grading. World J Urol 2015;33:1929–36.
   PubMed Web of Science ®Google Scholar
• Luchey AM, Manimala NJ, Dickinson S, Dhillon J, Agarwal G, Lockhart JL, et al. Change in management based on pathologic second opinion among bladder cancer patients presenting to a comprehensive cancer center: implications for clinical practice. Urology 2016;93:130–4.
   PubMed Web of Science ®Google Scholar
• Ricci S, Bruzzese D, Di Carlo A. Evaluation of MMP-2, MMP-9, TIMP-1, TIMP-2, NGAL and MMP-9/NGAL complex in urine and sera from patients with bladder cancer. Oncol Lett 2015;10:2527–32.
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Musquera M, Liu L, Vis AN, Zuiverloon TC, van Leenders GJ, et al. Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications. Mod Pathol 2015;28:695–705.
   PubMed Web of Science ®Google Scholar
• James AC, Gore JL. The costs of non-muscle invasive bladder cancer. Urol Clin North Am 2013;40:261–9.
   PubMed Web of Science ®Google Scholar
• Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim SP, Stenzl A, Lotan Y. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 2014;66:253–62.
   PubMed Web of Science ®Google Scholar
• Zuiverloon TC, Beukers W, van der Keur KA, Nieuweboer AJ, Reinert T, Dyrskjot L, et al. Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project. J Urol 2013;189:1945–51.
   PubMed Web of Science ®Google Scholar
• Karl A, Weidlich P, Buchner A, Hofmann T, Schneevoigt B, Stief C, Zaak D. Photodynamic diagnosis of the urinary bladder using flexible instruments: ready for the outpatient setting? J Clin Trials 2014;4:190.
   Google Scholar
• Hermann GG, Mogensen K, Toft BG, Glenthøj A, Pedersen HM. Outpatient diagnostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies. Scand J Urol Nephrol 2012;46:31–6.
   PubMed Web of Science ®Google Scholar
• Zare R, Kornmo T, Arstad C. Blue light flexible cystoscopy in bladder cancer in an outpatient setting (video case examples). Madrid, Spain: European Association of Urology Annual Meeting; 2015.
   Google Scholar
• Dansk V, Malmström P-U, Bläckberg M, Malmenäs M. Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden. Future Oncol 2016;12:1025–38.
   PubMed Web of Science ®Google Scholar